Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
BMC Endocrine Disorders20088:14

https://doi.org/10.1186/1472-6823-8-14

©  Williams-Herman et al; licensee BioMed Central Ltd. 2008

  • Received: 25 June 2008
  • Accepted: 27 October 2008
  • Published:
Open Peer Review reports

Abstract

Background

Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (AHAs) for the treatment of patients with type 2 diabetes. Type 2 diabetes is a life-long disease requiring chronic treatment and management. Therefore, robust assessment of the long-term safety and tolerability of newer therapeutic agents is of importance. The purpose of this analysis was to assess the safety and tolerability of sitagliptin by pooling 12 large, double-blind, Phase IIb and III studies up to 2 years in duration. Methods: This analysis included 6139 patients with type 2 diabetes receiving either sitagliptin 100 mg/day (N = 3415) or a comparator agent (placebo or an active comparator) (N = 2724; non-exposed group). The 12 studies from which this pooled population was drawn represent the double-blind, randomized, Phase IIB and III studies that included patients treated with the clinical dose of sitagliptin (100 mg/day) for at least 18 weeks up to 2 years and that were available in a single safety database as of November 2007. These 12 studies assessed sitagliptin as monotherapy, initial combination therapy with metformin, or add-on combination therapy with other oral AHAs (metformin, pioglitazone, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone). Patients in the non-exposed group were taking placebo, pioglitazone, metformin, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone. This safety analysis used patient-level data from each study to evaluate clinical and laboratory adverse experiences.

Results

For clinical adverse experiences, the incidence rates of adverse experiences overall, serious adverse experiences, and discontinuations due to adverse experiences were similar in the sitagliptin and non-exposed groups. The incidence rates of specific adverse experiences were also generally similar in the two groups, with the exception of an increased incidence rate of hypoglycemia observed in the non-exposed group. The incidence rates of drug-related adverse experiences overall and discontinuations due to drug-related adverse experiences were higher in the non-exposed group, primarily due to the increased incidence rate of hypoglycemia in this group. For cardiac- and ischemia-related adverse experiences (including serious events), there were no meaningful between-group differences. No meaningful differences between groups in laboratory adverse experiences, either summary measures or specific adverse experiences, were observed.

Conclusion

In patients with type 2 diabetes, sitagliptin 100 mg/day was well tolerated in clinical trials up to 2 years in duration.

Keywords

  • Metformin
  • Hypoglycemia
  • Exenatide
  • Sitagliptin
  • Vildagliptin

Background

Sitagliptin is an oral, once-daily and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of patients with type 2 diabetes [1]. Inhibition of DPP-4 activity by sitagliptin enhances fasting and postprandial levels of the intact incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) [2]. These incretins play a role in glucose homeostasis by increasing insulin release in response to a meal; GLP-1 also decreases glucagon release. Both of these effects are glucose-dependent [3]. In placebo-controlled trials up to 30 weeks in duration, sitagliptin improved fasting and postprandial glycemic control. Sitagliptin, as monotherapy or as add-on therapy to other oral antihyperglycemic agents (AHAs), including metformin, a thiazolidinedione, and a sulfonylurea, has a tolerability profile generally similar to placebo [4–13], although an increase in adverse experiences primarily due to an increase in hypoglycemia was observed when sitagliptin was added to ongoing therapy with a sulfonylurea [10]. Further, in a 52-week, active comparator-controlled trial, the addition of sitagliptin to metformin demonstrated similar efficacy, with a lower incidence rate of hypoglycemia and weight loss versus weight gain, relative to the addition of glipizide to metformin [14].

As type 2 diabetes is a chronic, progressive disease that requires long-term treatment and management, the long-term safety and tolerability of sitagliptin at the usual registered dose of 100 mg/day is of importance. In this report, the safety and tolerability of sitagliptin 100 mg/day were examined in a pooled analysis of patient-level data from 12 double-blind, randomized, Phase IIb and III studies up to 2 years in duration in patients with type 2 diabetes. This pooled analysis provides for a comparison of the safety and tolerability profile of patients treated with sitagliptin 100 mg/day relative to the safety and tolerability profile of patients who participated in these studies but were treated with other therapies (placebo or other oral AHAs), with both groups receiving diet and exercise counseling throughout the studies. The safety and tolerability of dose-adjusted sitagliptin as assessed over 54 weeks in a special populations study of 91 patients with moderate to severe and end-stage renal insufficiency have been reported elsewhere [15].

Methods

The present analysis focused on the safety and tolerability of the clinical dose of sitagliptin (100 mg/day) approved for use in this broad population of patients with type 2 diabetes [16]. The 12 studies from which this pooled population was drawn represent the double-blind, randomized, Phase IIB and III studies that included patients treated with the clinical dose of sitagliptin (100 mg/day) for at least 18 weeks up to 2 years and that were available in a single safety database as of November 2007. In these studies, patients received sitagliptin as monotherapy or in combination with other oral AHAs, depending upon the particular trial. Patients not receiving sitagliptin received a range of treatments, including placebo, pioglitazone, metformin, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone. This comparison group, patients not receiving sitagliptin, is referred to as the "non-exposed" group. The pooling was conducted by including, from each contributing study, parallel treatment groups of patients with exposure to sitagliptin 100 mg/day (100 mg q.d. [once daily] or 50 mg b.i.d. [twice daily]) that was concurrent to exposure to other treatments (either placebo or active-comparator, Table 1) for generally similar periods of time. Based upon data from a Phase IIb study showing a similar safety and efficacy profile for sitagliptin 100 mg/day administered as either 100 mg q.d. or 50 mg b.i.d. [8], data from these two treatment groups were pooled for this analysis. There were 3 studies in which sitagliptin was administered as 50 mg b.i.d., either alone or in combination with metformin: the 2 Phase IIb studies [6, 8], and the study of initial combination therapy with sitagliptin and metformin that simulated the b.i.d. administration of a fixed-dose combination of sitagliptin and metformin [12].
Table 1

Studies and treatment arms included in this pooled analysis

Study and Reference*

Study Design

Sitagliptin 100 mg/day Group

(N = 3415)

n

Non-exposed Group

(N = 2724)

n

P010: twice-daily dose-range finding [6]

106-week active-controlled period

• Sitagliptin 50 mg b.i.d. switched to 100 mg q.d.

122

• Glipizide

123

P014: once-daily dose-range finding [8]

12-week placebo-controlled period and 94-week active-controlled period

• Sitagliptin 100 mg q.d.

110

• Placebo (12 weeks) switched to metformin (94 weeks)

111

  

• Sitagliptin 50 mg b.i.d. switched to Sitagliptin 100 mg q.d.

111

  

P019: placebo-controlled add-on to pioglitazone study [11]

24-week placebo-controlled period

• Sitagliptin 100 mg q.d. + pioglitazone

175

• Placebo + pioglitazone

178

P020: placebo-controlled add-on to metformin study [9]

24-week placebo-controlled period and 80-week active-controlled period

• Sitagliptin 100 mg q.d. + metformin

464

• Placebo + metformin (24 weeks) switched to glipizide + metformin (80 weeks)

237

P021: placebo-controlled monotherapy study [4]

24-week placebo-controlled period

• Sitagliptin 100 mg q.d.

238

• Placebo

253

P023: placebo-controlled

18-week placebo-controlled period and 36-week active-controlled period

• Sitagliptin 100 mg q.d.

205

• Placebo (18 weeks) switched to pioglitazone (36 weeks)

110

P024: active-comparator controlled add-on to metformin study [14]

104-week active-controlled period

• Sitagliptin 100 mg q.d. + metformin

588

• Glipizide + metformin

584

P035: placebo-controlled add-on to glimepiride, alone or in combination with metformin [10]

24-week placebo-controlled period and 30-week active-controlled period

• Sitagliptin 100 mg q.d. + glimepiride (± metformin)

222

• Placebo + glimepiride (± metformin) (24 weeks) switched to pioglitazone + glimepiride (± metformin) (30 weeks)

219

P036: placebo- and active-controlled study of initial combination use of metformin and sitagliptin[12]

24 week placebo-controlled period and 30-week active-controlled period

• Sitagliptin 100 mg q.d.

179

• Placebo (24 weeks) switched to metformin 1000 mg

b.i.d. (30 weeks)

176

  

• Sitagliptin 50 mg

b.i.d./metformin 500 mg b.i.d.

190

• Metformin 500 mg b.i.d.

182

  

• Sitagliptin 50 mg

b.i.d./metformin 1000 mg b.i.d.

182

• Metformin 1000 mg b.i.d.

182

P040: placebo-controlled monotherapy study [39]

18-week placebo-controlled period

• Sitagliptin 100 mg q.d.

352

• Placebo

178

P052: placebo-controlled add-on to metformin and rosiglitazone study [40]

18-week placebo-controlled period

• Sitagliptin 100 mg q.d. + metformin and rosiglitazone

181

• Placebo + metformin and rosiglitazone

97

P053: placebo-controlled add-on to metformin study [13]

30-week placebo-controlled period

• Sitagliptin 100 mg q.d. + metformin

96

• Placebo + metformin

94

*References are for the initial phases of the studies that had extension or continuations phases. Studies P019, P040, and P053 did not have continuation phases. For Studies P052, patients continued their sitagliptin or placebo treatment in the currently ongoing continuation phase.

This safety analysis used patient-level data from each study for the evaluation of clinical and laboratory adverse experiences. Adverse experiences were encoded in these studies using the MedDRA (Medical Dictionary for Regulatory Activities; version 10.0) system, a medically validated terminology database developed by the International Conference on Harmonisation. Within this dictionary, adverse event terms are grouped by type of adverse experience (e.g., "Infections and Infestations" or "Investigations") or by body system (e.g., "Gastrointestinal [GI] Disorders" or "Cardiac Disorders"), with groupings referred to as "System Organ Classes" or SOCs. For adverse experiences reported by SOC, a patient was counted once if he/she experienced any adverse experiences included within the SOC (e.g., a patient with the separately reported adverse experiences of 'nausea' and 'abdominal pain' is included separately in the lines for each specific adverse experience but counted only once in the listing for the broader "GI Disorders" SOC, which summarizes the proportions of patients who experienced at least one GI adverse experience). Adverse experiences were expressed as incidence rates (i.e., number of patients with an event divided by total number of patients exposed). Differences in incidence rates between treatment groups and 95% confidence intervals (CI) were calculated using Wilson's score method [17], and clinical adverse experiences with between-treatment group differences in incidence rates for which the 95% CI excluded zero were tabulated. To provide more detail on the overall safety of sitagliptin, specific clinical and laboratory adverse experiences reported for at least 1% of patients in any group were summarized. Since drug-related and serious clinical adverse experiences are generally reported less frequently, these events were summarized using lower cut points (i.e., 0.5% and 0.2% of patients, respectively).

In most studies included in this analysis, glycemic rescue therapy was to be implemented based upon protocol-specified hyperglycemic criteria. The primary analysis in this pooled safety population focused on the results excluding data obtained from time points after a patient initiated rescue therapy to avoid the confounding influence of the rescue therapy.

To assess the robustness of the conclusions from the primary analysis, the results were also analyzed by including data obtained from time points after a patient initiated rescue therapy. An additional analysis, evaluating the number of events per 100 patient-years in study (event rates), was also performed.

Potential Mechanism-Based Adverse Experiences

Delayed gastric emptying associated with pharmacologic levels of intact GLP-1 has been associated with increased incidences of GI-related adverse experiences such as nausea and vomiting [3]. Since sitagliptin increases intact GLP-1 and GIP levels by 2- to 3-fold [2, 18], certain GI adverse experiences were pre-specified for statistical analysis (including diarrhea, nausea, vomiting and abdominal pain [including upper and lower abdominal pain and abdominal/stomach discomfort]) in the sitagliptin development program. Further, since cases of pancreatitis have been reported in association with treatment with a GLP-1 analogue [19, 20], this GI adverse experience was also of interest in this pooled analysis.

The DPP-4 enzyme (also referred to as the protein CD26) is expressed on activated T cells, and, although the role of DPP-4 enzyme activity in T cell function is not clear, it is unlikely related to the co-stimulatory function of CD26 [21, 22]. Animals genetically deficient in CD26 are healthy and fertile without an evident increase in infections [23], and immune function as well as lymph nodes, spleen, and bone marrow in animals treated with a selective DPP-4 inhibitor appear normal [24, 25]. Further, in vitro proliferation of human peripheral blood monocytes is unaffected by selective DPP-4 inhibition [24]. Given the possibility of immune alteration with DPP-4 inhibition, however, adverse experiences in the "Infection and Infestation" SOC were specifically reviewed in the present report.

Serious hypersensitivity reactions, including Stevens-Johnson syndrome, have been reported with the use of sitagliptin in the postmarketing environment [16]. While the causal relationship between sitagliptin and such adverse experiences voluntarily reported from a population of unknown size cannot be definitively established, skin-related adverse experiences were examined in the present pooled analysis. Skin-related findings are also of interest, as preclinical administration of some DPP-4 inhibitors other than sitagliptin (e.g., vildagliptin and PHX1149) [26, 27] had been associated with dose-dependent necrotic skin lesions when administered to monkeys. These preclinical findings have not been observed when sitagliptin was administered to monkeys [28], and an increased incidence of skin findings consistent with the preclinical lesions has not been reported in patients in controlled clinical studies with DPP-4 inhibitors, including studies with sitagliptin, vildagliptin, alogliptin, and saxagliptin.

It has been theorized that DPP-4 inhibition could lead to increased events of angioedema, particularly in patients concomitantly treated with angiotensin-converting enzyme (ACE) inhibitors (another class of agents with peptidase activity) [29]. Therefore, a potential association between ACE inhibitor use and the incidence of angioedema-related events (see Appendix I for list of events considered angioedema-related) was evaluated. For this analysis, angioedema-related events were evaluated for the periods with and without exposure to an ACE inhibitor. Exposure to an ACE inhibitor was defined as the total days of ACE inhibitor use during the double-blind treatment period. Patients contributed to patient-years of exposure to an ACE inhibitor for the actual period of time that they were reported to have been taking an ACE inhibitor and to patient-years of non-exposure for the actual period of time that they were reported not to have been taking an ACE inhibitor. Data were expressed as event rates for both incident angioedema-related events (all first events of angioedema) and total angioedema-related events (all events, including those occurring more than once for the same patient) per 100 patient-years of exposure.

Cardiovascular-related Adverse Experiences

Patients with type 2 diabetes are at increased risk for cardiovascular morbidity and mortality [30]. Recently, there has been increased focus on treatments for diabetes and cardiovascular risk. Therefore, the between-group differences in incidence rates of cardiac (e.g., all cardiac-related adverse experiences, including ischemic and non-ischemic events) and ischemia-related adverse experiences were evaluated in this pooled analysis. This analysis presents adverse experience terms as reported by the investigator; terms for ischemia-related events reported for these studies are found in Appendix II. No formal adjudication was performed.

Results

Patient Characteristics and Exposure

In this pooled analysis, there were 6139 patients overall, with 3415 in the sitagliptin 100-mg group and 2724 in the non-exposed group. At baseline, patients in the total cohort had an average age of 55 years (range: 19 to 87 years), a mean duration of diabetes of 5.5 years, and a mean A1C of 8.2%. Men comprised 55% of this cohort and the racial/ethnic breakdown was 57.4% White, 16.2% Asian, 15.2% Hispanic, 5.6% Black, and 5.6% "Other". There were no meaningful differences between treatment groups in these baseline characteristics or in the frequency or type of other medical conditions or medications used.

The mean exposure to drug and total patient-years in study were slightly greater in the sitagliptin group relative to the non-exposed group: 307.3 dosing days (range = 1 to 792) relative to 293.6 dosing days (1 to 801), respectively. In the sitagliptin group, 1343 patients were treated for at least 1 year, with 356 of these patients treated for 2 years. The corresponding numbers of patients in the non-exposed group were 981 and 290. The total duration of observation in study was 2994 patient-years for the sitagliptin group relative to 2270 patient-years for the non-exposed group. In these studies up to 2 years in duration, the proportions of patients discontinuing treatment overall were 34.9% in the sitagliptin group and 39.5% in the non-exposed group, with the reasons for discontinuations generally similar between groups (Table 2).
Table 2

Overall disposition of the 6139 randomized patients in the sitagliptin and non-exposed groups

 

Sitagliptin 100 mg

Non-Exposed

RANDOMIZED, N

3415

2724

 

n (%)

n (%)

DISCONTINUED*

1191 (34.9)

1076 (39.5)

Reason for discontinuation

  

   Clinical adverse experience

119 (3.5)

113 (4.1)

   Laboratory adverse experience

38 (1.1)

22 (0.8)

   Lack of efficacy†

458 (13.4)

381 (14.0)

   Patient discontinued for other

152 (4.5)

176 (6.5)

   Patient moved

33 (1.0)

19 (0.7)

   Patient withdrew consent

186 (5.4)

203 (7.4)

   Protocol specified discontinuation criteria

48 (1.4)

44 (1.6)

   Protocol deviation

58 (1.7)

50 (1.8)

   Lost to follow-up

97 (2.8)

65 (2.4)

   Site terminated

2 (0.1)

3 (0.1)

*To provide a complete accounting of the 6139 randomized patients, this table includes data from patients after they received glycemic rescue therapy, whereas the primary safety analysis focuses on results excluding data after patients received rescue therapy. These numbers include patients discontinued over periods of up to 2 years, including those patients who underwent glycemic rescue during the placebo-controlled phase and were ineligible in some studies to enter into the continuation phase.

†Includes patients not meeting the progressively stricter, protocol-specified, glycemic rescue criteria and/or not meeting the investigator's expectations of glycemic improvement.

Clinical Adverse Experiences in the Sitagliptin and Non-Exposed Treatment Groups

The following sections report the results from the primary safety analysis. The findings from the primary safety analysis (excluding data after glycemic rescue therapy) were generally consistent with those that included data after rescue therapy and with those examining the event rates per 100 patient-years (data not shown).

Summary measures of the incidence rates of adverse experiences overall, serious adverse experiences, and discontinuations due to adverse experiences were similar in the sitagliptin and non-exposed groups (Table 3). Drug-related adverse experiences and discontinuations due to drug-related adverse experiences were higher in non-exposed patients, primarily due to hypoglycemia in sulfonylurea-treated patients. In a few SOCs, there were small differences in the incidence rates of adverse experiences (Table 4). For the "Blood and Lymphatic System Disorders" SOC, a slightly higher incidence rate of the adverse experience of anemia in the sitagliptin group compared to the non-exposed group (0.4% vs. 0.1%, respectively; between-group difference [95% CI] = 0.3% [-0.0, 0.6]) accounted for a majority of the between-group difference. The between-group difference in incidence rate in the "Metabolism and Nutrition Disorders" SOC was primarily due to a higher incidence rate of hypoglycemia in the non-exposed group (10.9%) (primarily seen in sulfonylurea-treated patients) relative to the sitagliptin group (3.4%) (Table 5). For the "Investigations" SOC, 3 adverse experiences (blood glucose increased, blood glucose decreased, and weight increased) accounted for the higher incidence rate in the non-exposed group relative to the sitagliptin group (Table 6).
Table 3

Clinical adverse experience summary

 

Sitagliptin 100 mg

n (%)

(N = 3415)

Non-Exposed

n (%)

(N = 2724)

Difference in Sitagliptin

and Non-Exposed

% (95% CI)*

With one or more adverse experiences

2150 (63.0)

1711 (62.8)

0.1 (-2.3, 2.6)

With drug-related adverse experiences†

440 (12.9)

483 (17.7)

-4.8 (-6.7, -3.0)

With serious adverse experiences

230 (6.7)

184 (6.8)

-0.0 (-1.3, 1.2)

With serious drug-related adverse experiences†

8 (0.2)

8 (0.3)

-0.1 (-0.4, 0.2)

Who died

11 (0.3)

16 (0.6)

-0.3 (-0.7, 0.1)

Discontinued due to adverse experiences

106 (3.1)

101 (3.7)

-0.6 (-1.5, 0.3)

Discontinued due to drug-related adverse experiences

30 (0.9)

40 (1.5)

-0.6 (-1.2, -0.1)

Discontinued due to serious adverse experiences

51 (1.5)

47 (1.7)

-0.2 (-0.9, 0.4)

Discontinued due to serious drug-related adverse experiences

4 (0.1)

4 (0.1)

-0.0 (-0.3, 0.2)

CI = confidence interval

*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

†Determined by the investigator to be possibly, probably, or definitely drug-related.

Table 4

Summary of clinical adverse experiences by system organ class

System Organ Class

Sitagliptin 100 mg

n (%)

(N = 3415)

Non-Exposed

n (%)

(N = 2724)

Difference between Sitagliptin

and Non-Exposed

% (95% CI)*

Blood and Lymphatic System Disorders

33 (1.0)

11 (0.3)

0.6 (0.1, 1.0)

Cardiac Disorders

136 (4.0)

105 (3.9)

0.1 (-0.9, 1.1)

Congenital, Familial, and Genetic Disorders

7 (0.2)

4 (0.1)

0.1 (-0.2, 0.3)

Ear And Labyrinth Disorders

50 (1.5)

53 (1.9)

-0.5 (-1.2, 0.2)

Endocrine Disorders

9 (0.3)

15 (0.6)

-0.3 (-0.7, 0.0)

Eye Disorders

140 (4.1)

112 (4.1)

-0.0 (-1.0, 1.0)

Gastrointestinal Disorders

659 (19.3)

493 (18.1)

1.2 (-0.8, 3.1)

General Disorders And Administration Site Conditions

259 (7.6)

212 (7.8)

-0.2 (-1.6, 1.1)

Hepatobiliary Disorders

44 (1.3)

27 (1.0)

0.3 (-0.3, 0.8)

Immune System Disorders

32 (0.9)

25 (0.9)

0.0 (-0.5, 0.5)

Infections And Infestations

1179 (34.5)

897 (32.9)

1.6 (-0.8, 4.0)

Injury, Poisoning And Procedural Complications

290 (8.5)

222 (8.1)

0.3 (-1.1, 1.7)

Investigations

143 (4.2)

145 (5.3)

-1.1 (-2.2, -0.1)

Metabolism And Nutrition Disorders

219 (6.4)

373 (13.7)

-7.3 (-8.8, -5.8)

Musculoskeletal And Connective Tissue Disorders

576 (16.9)

434 (15.9)

0.9 (-0.9, 2.8)

Neoplasms Benign, Malignant And Unspecified†

76 (2.2)

44 (1.6)

0.6 (-0.1, 1.3)

Nervous System Disorders

433 (12.7)

344 (12.6)

0.1 (-1.6, 1.7)

Pregnancy, Puerperium, and Perinatal Conditions

1 (0.0)

2 (0.1)

-0.0 (-0.2, 0.1)

Psychiatric Disorders

143 (4.2)

121 (4.4)

-0.3 (-1.3, 0.8)

Renal And Urinary Disorders

99 (2.9)

74 (2.7)

0.2 (-0.7, 1.0)

Reproductive System And Breast Disorders

90 (2.6)

84 (3.1)

-0.4 (-1.3, 0.4)

Respiratory, Thoracic And Mediastinal Disorders

279 (8.2)

208 (7.6)

0.5 (-0.8, 1.9)

Skin And Subcutaneous Tissue Disorders

248 (7.3)

169 (6.2)

1.1 (-0.2, 2.3)

Social Circumstances

2 (0.1)

1 (0.0)

0.0 (-0.2, 0.2)

Surgical and Medical Procedures

3 (0.1)

1 (0.0)

0.1 (-0.1, 0.2)

Vascular Disorders

181 (5.3)

141 (5.2)

0.1 (-1.0, 1.2)

CI = confidence interval

*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

†For malignant tumors n (%): 31 (0.9%) in the sitagliptin group and 26 (1.0%) in the non-exposed group.

Table 5

Clinical adverse experiences for which the 95% confidence intervals around the difference in incidence rate exclude 0

Adverse Experience

Sitagliptin 100 mg

n (%)

(N = 3415)

Non-Exposed

n (%)

(N = 2724)

Difference in Sitagliptin

and Non-Exposed,

% (95% CI)*

Sitagliptin > Non-exposed

Atrial fibrillation†

18 (0.5)

5 (0.2)

0.3 (0.0, 0.7)

Asthenia

19 (0.6)

6 (0.2)

0.3 (0.0, 0.7)

Chest discomfort

9 (0.3)

1 (0.0)

0.2 (0.0, 0.5)

Tooth abscess‡

27 (0.8)

10 (0.4)

0.4 (0.0, 0.8)

Osteoarthritis

58 (1.7)

24 (0.9)

0.8 (0.2, 1.4)

Acne

7 (0.2)

0 (0)

0.2 (0.0, 0.4)

Dermatitis Contact

24 (0.7)

7 (0.3)

0.4 (0.1, 0.8)

Non-exposed > Sitagliptin

Bradycardia

0 (0)

4 (0.1)

-0.1 (-0.4, -0.0)

Goiter

1 (0.0)

6 (0.2)

-0.2 (-0.5, -0.0)

Change in bowel habit

0 (0)

4 (0.1)

-0.1 (-0.4, -0.0)

Blood glucose decreased

13 (0.4)

28 (1.0)

-0.6 (-1.1, -0.2)

Blood glucose increased

42 (1.2)

51 (1.9)

-0.6 (-1.3, -0.0)

Weight increased

12 (0.4)

20 (0.7)

-0.4 (-0.8, -0.0)

Hypoglycemia

117 (3.4)

296 (10.9)

-7.4 (-8.8, -6.1)

Sinus headache

3 (0.1)

12 (0.4)

-0.4 (-0.7, -0.1)

Prostatitis

3 (0.1)

9 (0.3)

-0.2 (-0.5, -0.0)

Balanitis

0 (0)

4 (0.1)

-0.1 (-0.4, -0.0)

Hyperkeratosis

0 (0)

8 (0.3)

-0.3 (-0.6, -0.1)

CI = confidence interval

*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

†When atrial fibrillation and atrial flutter were combined, the incidence rates were 0.5% and 0.3% for the sitagliptin and non-exposed groups, respectively (between-group difference [95% CI] = 0.3 [-0.1, 0.6]).

‡When tooth abscess and tooth infection were combined, the incidence rates were 1.3% and 0.9% for the sitagliptin and non-exposed groups, respectively (between-group difference [95% CI] = 0.4 [-0.1, 1.0]).

Table 6

Clinical adverse experiences occurring at an incidence rate ≥1% in any group

Adverse Experience

Sitagliptin 100 mg

n (%)

(N = 3415)

Non-Exposed

n (%)

(N = 2724)

Difference between Sitagliptin

and Non-Exposed,

% (95% CI)*

Vertigo

24 (0.7)

27 (1.0)

-0.3 (-0.8, 0.2)

Abdominal Pain

39 (1.1)

33 (1.2)

-0.1 (-0.6, 0.5)

Abdominal Pain Upper

59 (1.7)

33 (1.2)

0.5 (-0.1, 1.1)

Constipation

79 (2.3)

47 (1.7)

0.6 (-0.1, 1.3)

Diarrhea

170 (5.0)

144 (5.3)

-0.3 (-1.4, 0.8)

Dyspepsia

70 (2.0)

40 (1.5)

0.6 (-0.1, 1.2)

Gastritis

36 (1.1)

30 (1.1)

-0.0 (-0.6, 0.5)

Nausea

85 (2.5)

70 (2.6)

-0.1 (-0.9, 0.7)

Toothache

35 (1.0)

33 (1.2)

-0.2 (-0.8, 0.3)

Vomiting

51 (1.5)

34 (1.2)

0.2 (-0.4, 0.8)

Fatigue

56 (1.6)

53 (1.9)

-0.3 (-1.0, 0.4)

Peripheral Edema

62 (1.8)

54 (2.0)

-0.2 (-0.9, 0.5)

Bronchitis

135 (4.0)

83 (3.0)

0.9 (-0.0, 1.8)

Cellulitis

28 (0.8)

26 (1.0)

-0.1 (-0.6, 0.3)

Gastroenteritis

68 (2.0)

48 (1.8)

0.2 (-0.5, 0.9)

Gastroenteritis Viral

29 (0.8)

27 (1.0)

-0.1 (-0.7, 0.3)

Influenza

145 (4.2)

127 (4.7)

-0.4 (-1.5, 0.6)

Nasopharyngitis

244 (7.1)

162 (5.9)

1.2 (-0.1, 2.4)

Pharyngitis

52 (1.5)

35 (1.3)

0.2 (-0.4, 0.8)

Sinusitis

80 (2.3)

60 (2.2)

0.1 (-0.6, 0.9)

Upper Respiratory Tract Infection

265 (7.8)

228 (8.4)

-0.6 (-2.0, 0.8)

Urinary Tract Infection

134 (3.9)

100 (3.7)

0.3 (-0.7, 1.2)

Viral Infection

36 (1.1)

21 (0.8)

0.3 (-0.2, 0.8)

Blood Glucose Decreased

13 (0.4)

28 (1.0)

-0.6 (-1.1, -0.2)

Blood Glucose Increased

42 (1.2)

51 (1.9)

-0.6 (-1.3, -0.0)

Hyperglycemia

34 (1.0)

39 (1.4)

-0.4 (-1.0, 0.1)

Hypoglycemia†

117 (3.4)

296 (10.9)

-7.4 (-8.8, -6.1)

Arthralgia

113 (3.3)

92 (3.4)

-0.1 (-1.0, 0.8)

Back Pain

142 (4.2)

108 (4.0)

0.2 (-0.8, 1.2)

Muscle Spasms

38 (1.1)

35 (1.3)

-0.2 (-0.8, 0.4)

Musculoskeletal Pain

54 (1.6)

40 (1.5)

0.1 (-0.5, 0.7)

Myalgia

38 (1.1)

29 (1.1)

0.0 (-0.5, 0.6)

Neck Pain

23 (0.7)

26 (1.0)

-0.3 (-0.8, 0.2)

Osteoarthritis

58 (1.7)

24 (0.9)

0.8 (0.2, 1.4)

Pain in Extremity

84 (2.5)

53 (1.9)

0.5 (-0.2, 1.2)

Dizziness

86 (2.5)

63 (2.3)

0.2 (-0.6, 1.0)

Headache

169 (4.9)

129 (4.7)

0.2 (-0.9, 1.3)

Hypoesthesia

24 (0.7)

31 (1.1)

-0.4 (-1.0, 0.0)

Anxiety

32 (0.9)

27 (1.0)

-0.1 (-0.6, 0.4)

Depression

40 (1.2)

29 (1.1)

0.1 (-0.4, 0.6)

Insomnia

44 (1.3)

35 (1.3)

0.0 (-0.6, 0.6)

Cough

88 (2.6)

73 (2.7)

-0.1 (-0.9, 0.7)

Pharyngolaryngeal Pain

44 (1.3)

34 (1.2)

0.0 (-0.5, 0.6)

Rash

35 (1.0)

24 (0.9)

0.1 (-0.4, 0.6)

Hypertension

110 (3.2)

89 (3.3)

-0.0 (-1.0, 0.8)

CI = confidence interval; *Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

†Includes studies in which a sulfonylurea was an active comparator or a background agent.

The most commonly reported adverse experiences in either group were hypoglycemia, upper respiratory tract infection, and nasopharyngitis (Table 6). Of these events, only nasopharyngitis occurred more frequently in the sitagliptin group, although the 95% CI around the between-group difference included 0 (between-group difference [95% CI] = 1.2% [-0.1, 2.4]. For specific clinical adverse experiences reported more frequently in a treatment group and for which the 95% CI around the between-group difference excluded 0, there were 7 specific adverse experiences that were higher in the sitagliptin group and 11 that were higher in the non-exposed group (Table 5). The largest between-group difference (7.4%) was observed for the adverse experience of hypoglycemia, which occurred at a higher incidence rate in the non-exposed group; otherwise the between-group differences in incidence rates were small (< 1%; Table 5). In the development program for sitagliptin, an episode of hypoglycemia was defined as an episode with symptoms of hypoglycemia assessed by the investigator as a clinical adverse experience of hypoglycemia based upon review of the patient's hypoglycemia log. Incidence rates of hypoglycemia were based upon all reports of hypoglycemia; a concurrent fingerstick glucose was not required. The incidence rates of hypoglycemia were driven largely by the use of a sulfonylurea as a comparator agent or as background therapy. Of the 296 patients in the non-exposed group having at least one episode of hypoglycemia, 239 (81%) had an episode while treated with a sulfonylurea. For the patients not treated with a sulfonylurea, the incidence rates for hypoglycemia were 2.6% (n/N: 87/3298) and 2.3% (50/2428) in the sitagliptin and non-exposed groups, respectively. The incidence rates of specific clinical adverse experiences occurring in at least 1% of patients in either group are listed in Table 6.

The incidence rate of drug-related clinical adverse experiences overall was higher in the non-exposed group (17.7%) compared with the sitagliptin group (12.9%), primarily due to reports of hypoglycemia and blood glucose decreased. Drug-related adverse experiences that occurred at an incidence rate of at least 0.5% in either group are listed in Table 7.
Table 7

Clinical adverse experiences considered to be related to study drug† that occurred at an incidence rate of ≥0.5% in any group

 

Sitagliptin 100 mg

n (%)

(N = 3415)

Non-Exposed

n (%)

(N = 2724)

Difference between Sitagliptin

and Non-Exposed

% (95% CI)*

Abdominal Pain Upper

18 (0.5)

11 (0.4)

0.1 (-0.2, 0.5)

Constipation

25 (0.7)

13 (0.5)

0.3 (-0.2, 0.7)

Diarrhea

42 (1.2)

45 (1.7)

-0.4 (-1.1, 0.2)

Dyspepsia

19 (0.6)

13 (0.5)

0.1 (-0.3, 0.4)

Nausea

33 (1.0)

31 (1.1)

-0.2 (-0.7, 0.3)

Fatigue

19 (0.6)

20 (0.7)

-0.2 (-0.6, 0.2)

Peripheral Edema

11 (0.3)

16 (0.6)

-0.3 (-0.7, 0.1)

Blood Glucose

6 (0.2)

16 (0.6)

-0.4 (-0.8, -0.1)

Decreased

   

Hypoglycemia‡

87 (2.5)

203 (7.5)

-4.9 (-6.1, -3.8)

Dizziness

17 (0.5)

13 (0.5)

0.0 (-0.4, 0.4)

Headache

37 (1.1)

29 (1.1)

0.0 (-0.5, 0.5)

CI = confidence interval

*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

†Determined by the investigator to be possibly, probably, or definitely drug-related.

‡Includes studies in which a sulfonylurea was an active comparator or a background agent.

The incidence rate of serious clinical adverse experiences overall was approximately 7% in each treatment group. A review of specific serious clinical adverse experiences irrespective of the relationship to study drug that occurred at an incidence rate of at least 0.2% did not reveal any notable between-group differences (Table 8).
Table 8

Serious clinical adverse experiences irrespective of relationship to study drug that occurred at an incidence rate of ≥0.2% in any group

 

Sitagliptin 100 mg

n (%)

(N = 3415)

Non-Exposed

n (%)

(N = 2724)

Difference between Sitagliptin

and Non-Exposed

% (95% CI)*

Coronary Artery Disease

5 (0.1)

7 (0.3)

-0.1 (-0.4, 0.1)

Myocardial Infarction

4 (0.1)

5 (0.2)

-0.1(-0.3, 0.1)

Non-cardiac Chest Pain

4 (0.1)

9 (0.3)

-0.2 (-0.5, 0.0)

Cholelithiasis

6 (0.2)

2 (0.1)

0.1 (-0.1, 0.3)

Pneumonia

4 (0.1)

5 (0.2)

-0.1 (-0.3, 0.1)

CI = confidence interval

*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

Potentially Mechanism-Based Adverse Experiences

The incidence rates of GI adverse experiences did not meaningfully differ between groups (Tables 4, 5, 6). For the pre-specified GI adverse experiences (diarrhea, nausea, vomiting and abdominal pain [including upper and lower abdominal pain and abdominal/stomach discomfort]), the incidence rates were generally similar between groups (Table 6). In the sitagliptin and non-exposed groups, the incidence rates of pancreatitis (0.1% and 0%, respectively), acute pancreatitis (0% and 0.1%, respectively) and chronic pancreatitis (0.1% and 0%, respectively) were low and not meaningfully different between the groups.

The overall incidence rates and intensity of adverse experiences of infection were similar in the two treatment groups, as, in general, were the frequencies and particular types of infections reported (Table 4 and Table 6). Further, the incidence rates of adverse experiences of infection that were reported as serious or that led to discontinuation were similar between groups. In addition, there was no evident increase in the frequency of specific types of infections suggestive of immune suppression (e.g., herpes zoster) between groups. As noted above, the incidence rate of the adverse experience of nasopharyngitis was slightly higher in the sitagliptin group, but in both treatment groups the events were generally mild in intensity and similar in duration, generally occurring as isolated events and after similar time periods following study initiation, and did not recur more frequently in patients in the sitagliptin group relative to those in the non-exposed group.

The overall incidence rate of adverse experiences in the "Skin and Subcutaneous Tissue Disorders" SOC was not meaningfully different between groups (Table 4). Two adverse experiences (acne and contact dermatitis [with approximately half of the events being "poison ivy/oak"]) were reported more frequently in the sitagliptin group compared with the non-exposed group, whereas hyperkeratosis was reported more frequently in the non-exposed group (Table 5). Rash was the only skin-related adverse experience reported by at least 1% of the patients in either group (Table 6), with an incidence rate of 1.0% in the sitagliptin group and 0.9% in the non-exposed group. No adverse experiences of Stevens-Johnson syndrome were reported in patients in the clinical trials that were pooled for this report; one event of erythema multiforme was reported for a patient in the non-exposed group. No adverse experiences consistent with the lesions observed during the preclinical development of some other (non-sitagliptin) DPP-4 inhibitors were reported.

For the analysis of angioedema-related events and the relationship of these events to concurrent treatment with ACE inhibitors, approximately 33% of patients were on an ACE inhibitor at baseline and approximately 36% were on an ACE inhibitor at any time during the studies (for a total of 1,023 and 779 patient-years on an ACE inhibitor for the sitagliptin and non-exposed groups, respectively). Among the 6139 patients included in this pooled analysis, there were 54 incident angioedema-related events, 16 of which occurred in patients concurrently taking an ACE inhibitor. The number of incident angioedema-related events per 100 patient-years while a patient was on an ACE inhibitor was the same (0.9) in both groups. The total numbers of angioedema-related events per 100 patient-years while a patient was on an ACE inhibitor were also similar in the sitagliptin (1.1) and non-exposed (0.9) groups. For patients not on an ACE inhibitor, the numbers of incident angioedema-related events per 100 patient-years were 1.1 in the sitagliptin group and 1.3 in the non-exposed group.

Cardiovascular-related Adverse Experiences

The incidence rates of overall and serious adverse experiences in the "Cardiac Disorders" SOC were similar between groups (Table 4), with the overall incidence rates of serious adverse experiences in this SOC being 1.2% in the sitagliptin group and 1.5% in the non-exposed group (between-group difference [95% CI] = -0.3% [-1.0, 0.3]). In an analysis in which ischemia-related adverse experiences overall were assessed, the incidence rates were 2.0% in the sitagliptin group and 2.3% in the non-exposed group (between-group difference [95% CI] = -0.2% [-1.0, 0.5]). For the serious ischemia-related adverse experiences, the incidence rates were 1.1% in the sitagliptin group and 1.5% in the non-exposed group (between-group difference [95% CI] = -0.4% [-1.0, 0.2]). There were 3 patients (0.09%) in the sitagliptin group (2 with ischemic stroke and 1 with myocardial infarction) with a fatal ischemic event compared with 7 patients (0.26%) in the non-exposed group (4 with myocardial infarction, 1 with myocardial ischemia, and 2 with sudden cardiac death).

Laboratory Adverse Experiences in the Sitagliptin and Non-Exposed Treatment Groups

Summary measures of the incidence rates of laboratory adverse experiences overall, serious laboratory adverse experiences, and discontinuations due to laboratory adverse experiences were similar in the two groups (Table 9). There were no meaningful between-group differences in the number of laboratory adverse experiences reported with an incidence rate of at least 1% (Table 10). For hepatic transaminases, the proportions of patients in the sitagliptin and non-exposed groups with their last measurement (obtained either at time of discontinuation or at the final scheduled study visit) of ALT > 3 times the upper limit of normal (3xULN) were 0.7% and 0.8%, respectively; the proportions with last AST measurement > 3xULN were 0.4% and 0.2%, respectively. The number of patients meeting the definition of Hy's Rule (i.e., an ALT and/or AST measurement > 3xULN and a bilirubin > 2xULN) at any time during the study was 2 in the sitagliptin group (with both cases resolving while continuing treatment; 1 patient had suspected concurrent bacteremia and a history of steatohepatitis, and the other had elevated ALT/AST and alkaline phosphatase prior to randomization) and 1 in the non-exposed group (in a patient with concurrent diagnosis of a liver abscess).
Table 9

Laboratory adverse experience summary

 

Sitagliptin 100 mg

n (%)

(N = 3375)

Non-Exposed

n (%)

(N = 2680)

Difference in Sitagliptin

and Non-Exposed

% (95% CI)*

With one or more adverse experiences

378 (11.2)

293 (10.9)

0.3 (-1.3, 1.8)

With drug-related adverse experiences†

102 (3.0)

78 (2.9)

0.1 (-0.8, 1.0)

With serious adverse experiences

3 (0.1)

0 (0)

0.1 (-0.1, 0.3)

With serious drug-related adverse experiences†

0 (0)

0 (0)

0.0 (-0.1, 0.1)

Who died

0 (0)

0 (0)

0.0 (-0.1, 0.1)

Discontinued due to adverse experiences

36 (1.1)

18 (0.7)

0.4 (-0.1, 0.9)

Discontinued due to drug-related adverse experiences

16 (0.5)

9 (0.3)

0.1 (-0.2, 0.5)

Discontinued due to serious adverse experiences

0 (0)

0 (0)

0.0 (-0.1, 0.1)

Discontinued due to serious drug-related adverse experiences

0 (0)

0 (0)

0.0 (-0.1, 0.1)

CI = confidence interval

*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

†Determined by the investigator to be possibly, probably, or definitely drug-related.

Table 10

Laboratory adverse experiences occurring at an incidence rate of ≥1% in any group

Adverse Experience

Sitagliptin 100 mg

n/N (%)

Non-Exposed

n/N (%)

Difference between Sitagliptin

and Non-Exposed,

% (95% CI)*

Alanine Aminotransferase Increased

51/3365 (1.5)

37/2672 (1.4)

0.1 (-0.5, 0.7)

Aspartate Aminotransferase Increased

35/3365 (1.0)

26/2672 (1.0)

0.1 (-0.5, 0.6)

Blood Uric Acid Increased

37/3364 (1.1)

22/2672 (0.8)

0.3 (-0.2, 0.8)

Creatine Phosphokinase Increased

22/819 (2.7)

11/619 (1.8)

0.9 (-0.7, 2.5)

Creatinine Clearance Estimation Decreased

31/3243 (1.0)

14/2551 (0.5)

0.4 (-0.1, 0.9)

Fasting Blood Glucose Increased

52/3370 (1.5)

63/2675 (2.4)

-0.8 (-1.6, 0.1)

Low Density Lipoprotein Increased

5/185 (2.7)

2/169 (1.2)

1.5 (-1.9, 5.1)

Protein Urine Present

19/1541 (1.2)

7/1209 (0.6)

0.7 (-0.1, 1.4)

Urine Microalbumin Present

2/228 (0.9)

9/251 (3.6)

-2.7 (-5.9, 0.1)

CI = confidence interval

Data are number of patients with a laboratory adverse experience/number of patients with laboratory measurement expressed as a percentage (n/N [%]).

*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.

Discussion

In this pooled analysis of clinical studies up to 2 years in duration, treatment with sitagliptin 100 mg/day was found to be well tolerated, with generally similar incidence rates of clinical and laboratory adverse experiences in patients treated with sitagliptin relative to those not exposed to sitagliptin. There was a higher incidence rate of drug-related adverse experiences in the non-exposed group, primarily due to the increased incidence rate of hypoglycemia in studies in which a sulfonylurea was used as an active comparator.

In previously reported placebo-controlled trials with sitagliptin as monotherapy, as initial combination therapy with metformin, or as an add-on therapy to agents not associated with hypoglycemia (e.g., metformin, a thiazolidinedione), the incidence rate of hypoglycemia with sitagliptin was low and similar to placebo [4–9, 11–13]. This low incidence rate of hypoglycemia observed with sitagliptin is consistent with its glucose-dependent mechanism of action [31]. When sitagliptin was added to ongoing therapy with a sulfonylurea, there was an increase in the incidence rate of hypoglycemia compared to the addition of placebo [10]. This phenomenon has been observed in trials of other AHAs (e.g., metformin, thiazolidinediones, and exenatide), which themselves are not associated with hypoglycemia, when they are added to a sulfonylurea agent [32–34]. In the present pooled analysis, the aggregate incidence rate of hypoglycemia in the sitagliptin group reflects the incidence rates across many studies with various treatment paradigms, including the study in which sitagliptin was added on to a sulfonylurea.

GI side effects are observed with different AHAs, including metformin and α-glucosidase inhibitors [35]. GLP-1 analogues such as exenatide produce levels of GLP-1 activity that are far in excess of physiologic levels and are associated with an increased incidence of nausea and vomiting [3]. In this pooled analysis, the incidence rates of GI adverse experiences, including nausea and vomiting, were similar in the sitagliptin and the non-exposed groups. This was not unexpected because the increased levels of active GLP-1 and GIP observed with the use of DPP-4 inhibitors remain within a physiologic range [3]. Consistent with these findings, when sitagliptin was co-administered with metformin, the GI adverse experience profile of the combination was similar to that of metformin alone [9, 12, 13].

Inhibition of DPP-4 with a highly selective compound has been shown not to alter measures of immune function in animals in vivo and in human immune cells in vitro [24, 25]. Moreover, mice completely lacking the CD26 molecule are healthy and fertile [23, 36]. Consistent with these observations, in the present pooled analysis there were no meaningful differences observed between treatment groups in the incidence rate, severity, and type of infections. Amori et al. suggested an increased risk for certain infections (nasopharyngitis and urinary tract infection) with DPP-4 inhibitors (including sitagliptin and vildagliptin) in a recent meta-analysis of efficacy and safety of incretin-based therapies [37]. In the current analysis, only a small numeric increase in the incidence rate of nasopharyngitis in the sitagliptin group was observed, while the incidence rates of urinary tract infections were similar in the two groups. Differences between the current findings and those of Amori et al. may be due to several factors, including the larger cohort of patients followed for a longer duration in the present analysis of clinical trials of sitagliptin. Further, the present analysis included all available clinical trial safety data for the specified populations while the Amori meta-analysis could have only included selected adverse experiences meeting different criteria for inclusion in the source manuscripts referenced.

Researchers have suggested that reduced DPP-4 enzyme activity and DPP-4 enzyme deficiency increase ACE inhibitor-induced angioedema in rats and potentially humans [29, 38]. These authors hypothesized that the concomitant use of DPP-4 inhibitors and ACE inhibitors could increase the risk of angioedema-related adverse experiences. The clinical experience reported in the present analysis does not support this hypothetical association. Moreover, a higher rate of angioedema-related events in sitagliptin-treated patients, regardless of ACE inhibitor use, was not observed in the present analysis. Hypersensitivity reactions with administration of sitagliptin (including those considered as severe) have been reported based upon postmarketing surveillance. In the current pooled analysis of events reported from controlled clinical trials, hypersensitivity events occurred with similar incidence rates in patients taking sitagliptin relative to the non-exposed group.

Although the studies in this analysis were not cardiovascular outcome trials, but rather trials assessing the overall safety and efficacy of sitagliptin 100 mg/day, there were no meaningful differences between groups in the incidence rates of cardiac-related or ischemia-related adverse experiences.

Conclusion

In patients with type 2 diabetes, sitagliptin 100 mg/day was well tolerated as monotherapy, as initial combination therapy, and as add-on therapy in double-blind, randomized clinical studies up to 2 years in duration. The safety of sitagliptin continues to be monitored in ongoing clinical studies and through postmarketing surveillance.

Appendix 1. List of terms* used in the angioedema-related adverse events analysis

Eye disorders system organ class (SOC)

Eye edema, Eye swelling, Eyelid edema

Immune system disorders SOC

Anaphylactic reaction, Angioedema, Drug hypersensitivity, Hypersensitivity

Skin and subcutaneous tissue disorders SOC

Face edema, Periorbital edema, Swelling face, Urticaria, Urticaria generalized

*From the adverse experiences reported in this pooled analysis, these reported terms were identified as angioedema-related.

Appendix 2. List of terms* used in the ischemia-related adverse events analysis

Vascular disorders SOC

Aortic arteriosclerosis, Aortic stenosis, Arteriosclerosis, Arteriosclerosis obliterans, Extremity necrosis, Iliac artery stenosis, Intermittent claudication, Leriche syndrome, Peripheral arterial occlusive disease, Peripheral ischemia

Nervous system disorders SOC

Carotid artery disease, Carotid artery stenosis, Cerebellar infarction, Cerebral infarction, Cerebrovascular accident, Ischemic stroke, Lacunar infarction, Thalamic infarction, Transient ischemic attack, Vertebrobasilar insufficiency

Cardiac disorders SOC**

Acute coronary syndrome, Acute myocardial infarction, Angina pectoris, Angina unstable, Arteriosclerosis coronary artery, Coronary artery disease, Coronary artery insufficiency, Coronary artery occlusion, Coronary artery stenosis, Ischemic cardiomyopathy, Myocardial infarction, Myocardial ischemia, Silent myocardial infarction, Ventricular tachycardia

General disorders and administration site conditions SOC

Sudden cardiac death

*From the adverse experiences reported in this pooled analysis, these reported terms were identified as ischemia-related.

**One patient in the non-exposed group with sepsis and multi-organ failure with cause of death reported as 'cardio-respiratory arrest' was not included in the ischemia-related analyses.

Declarations

Acknowledgements

The studies in this pooled analysis were sponsored by Merck & Co., Inc., Whitehouse Station, NJ. The authors gratefully acknowledge Rinki Jajoo, Sheng Zhang, Mary Anne Rutkowski and Kathy Harkins for programming support.

Authors’ Affiliations

(1)
Merck Research Laboratories, Rahway, NJ, USA

References

  1. Herman GA, Stein PP, Thornberry NA, Wagner JA: Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther. 2007, 81: 761-767. 10.1038/sj.clpt.6100167.View ArticlePubMedGoogle Scholar
  2. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M: Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharm Therap. 2005, 78: 675-688. 10.1016/j.clpt.2005.09.002.View ArticlePubMedGoogle Scholar
  3. Drucker DJ, Nauck MA: GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet. 2006, 368: 1696-1705. 10.1016/S0140-6736(06)69705-5.View ArticlePubMedGoogle Scholar
  4. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006, 29: 2632-2637. 10.2337/dc06-0703.View ArticlePubMedGoogle Scholar
  5. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006, 49: 2564-2571. 10.1007/s00125-006-0416-z.View ArticlePubMedGoogle Scholar
  6. Scott R, Wu M, Sanchez M, Stein PP: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007, 61: 171-180. 10.1111/j.1742-1241.2006.01246.x.View ArticlePubMedGoogle Scholar
  7. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N: Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008, 79: 291-298. 10.1016/j.diabres.2007.08.021.View ArticlePubMedGoogle Scholar
  8. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP: Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007, 23: 1329-1339. 10.1185/030079907X188152.View ArticlePubMedGoogle Scholar
  9. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care. 2006, 29: 2638-2643. 10.2337/dc06-0706.View ArticlePubMedGoogle Scholar
  10. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007, 9: 733-745. 10.1111/j.1463-1326.2007.00744.x.View ArticlePubMedGoogle Scholar
  11. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein PP: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-Blind, placebo-controlled parallel group study. Clin Ther. 2006, 28: 1556-1568. 10.1016/j.clinthera.2006.10.007.View ArticlePubMedGoogle Scholar
  12. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, for the Sitagliptin 036 Study Group: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007, 30: 1979-1987. 10.2337/dc07-0627.View ArticlePubMedGoogle Scholar
  13. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM: Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008, 24: 537-550. 10.1185/030079908X260925.View ArticlePubMedGoogle Scholar
  14. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007, 9: 194-205. 10.1111/j.1463-1326.2006.00704.x.View ArticlePubMedGoogle Scholar
  15. Chan JCN, Scott R, Arjona-Ferreira JC, Sheng D, Gonzalez E, Davies MJ: Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008, 10: 545-555. 10.1111/j.1463-1326.2008.00914.x.View ArticlePubMedGoogle Scholar
  16. Product Information: JANUVIA (sitagliptin). 2007, Whitehouse Station, NJ, Merck & Co., IncGoogle Scholar
  17. Newcombe RG: Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998, 17: 873-890. 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I.View ArticlePubMedGoogle Scholar
  18. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao PL: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006, 91: 4612-4619. 10.1210/jc.2006-1009.View ArticlePubMedGoogle Scholar
  19. Denker PS, Dimarco PE: Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care. 2006, 29: 471-10.2337/diacare.29.02.06.dc05-2043.View ArticlePubMedGoogle Scholar
  20. Ahmad SR, Swann J: Exenatide and rare adverse events. N Engl J Med. 2008, 358: 1970-1971.PubMedGoogle Scholar
  21. Gorrell MD, Gysbers V, McCaughan GW: CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol. 2001, 54: 249-264. 10.1046/j.1365-3083.2001.00984.x.View ArticlePubMedGoogle Scholar
  22. Boonacker EP, Wierenga EA, Smits HH, Van Noorden CJ: CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem. 2002, 50: 1169-1177.View ArticlePubMedGoogle Scholar
  23. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA. 2000, 97: 6874-6879. 10.1073/pnas.120069197.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005, 54: 2988-2994. 10.2337/diabetes.54.10.2988.View ArticlePubMedGoogle Scholar
  25. Vora KA, Porter G, Peng R, Cui Y, Eiermann G, Zaller DM: Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact the ability to mount T cell-dependent immune responses. Diabetes.Google Scholar
  26. European Medicines Agency (EMEA): Galvus (vildagliptin) – European Public Assessment Report (EPAR) – Scientific Discussion. 7-[http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf]
  27. Phenomix Corp: Securities Registration Statement (S-1) – Risk Factors. 9-[http://sec.edgar-online.com/2008/01/25/0001193125-08-012530/Section8.asp]
  28. FDA – CDER: Januvia (sitagliptin phosphate): Application Number 21-995 – Medical Review. 23-[http://www.fda.gov/cder/foi/nda/2006/021995s000_MedR.pdf]
  29. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J: Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008, 51: 141-147. 10.1161/HYPERTENSIONAHA.107.096552.View ArticlePubMedGoogle Scholar
  30. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.View ArticlePubMedGoogle Scholar
  31. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993, 36: 741-744. 10.1007/BF00401145.View ArticlePubMedGoogle Scholar
  32. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004, 27: 2628-2635. 10.2337/diacare.27.11.2628.View ArticlePubMedGoogle Scholar
  33. Roberts VL, Stewart J, Issa M, Lake B, Melis R: Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2005, 27: 1535-1547. 10.1016/j.clinthera.2005.10.017.View ArticlePubMedGoogle Scholar
  34. Lewin A, Lipetz R, Wu J, Schwartz S: Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. Clin Ther. 2007, 29: 844-855. 10.1016/j.clinthera.2007.05.013.View ArticlePubMedGoogle Scholar
  35. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002, 287: 360-372. 10.1001/jama.287.3.360.View ArticlePubMedGoogle Scholar
  36. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA. 2003, 100: 6825-6830. 10.1073/pnas.0631828100.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007, 298: 194-206. 10.1001/jama.298.2.194.View ArticlePubMedGoogle Scholar
  38. Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T: Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol. 2007, 120: 403-408. 10.1016/j.jaci.2007.04.012.View ArticlePubMedGoogle Scholar
  39. Yang W, Mohan V, Son HY, Liu J, Langdon RB, Stein P: Sitagliptin monotherapy significantly improves glycemic control and beta-cell function, and is well tolerated in patients with type 2 diabetes in China, India, and Korea (abstract). ASEAN Federation of Endocrine Societies. 2007, 24 (Suppl 1): 90-Google Scholar
  40. Dobs A, Goldstein BJ, Wieczorek L, Golm G, Davies MJ, Williams-Herman D: Triple combination therapy with sitagliptin, metformin, and rosiglitazone improves glycemic control in patients with type 2 diabetes (abstract). Diabetes. 2008, 57 (Suppl 1): A595-A596.Google Scholar

    41. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6823/8/14/prepub

Copyright

© Williams-Herman et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us